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Abstract
Staphylococcus aureus has developed resistance towards the most commonly used
anti-staphylococcal antibiotics. Therefore, there is an urgent need to find new treatment
opportunities. A new approach relies on the use of helper compounds, which are able to
potentiate the effect of antibiotics. A well-studied helper compound is thioridazine, which
potentiates the effect of the β-lactam antibiotic dicloxacillin against Methicillin-resistant
Staphylococcus aureus (MRSA). In order to identify thioridazine’s mechanism of action
and how it potentiates the effect of dicloxacillin, we generated thioridazine resistant strains
of MRSA USA300 by serial passage experiments. Selected strains were whole-genome
sequenced to find mutations causing thioridazine resistance. Genes observed to be
mutated were attempted deleted in MRSA USA300. The cls gene encoding a cardiolipin
synthase important for synthesis of the membrane lipid cardiolipin was found to be
mutated in thioridazine resistant strains. Deletion of this gene resulted in a two-fold
increased Minimum inhibitory concentrations (MIC) value for thioridazine compared to the
wild type and decreased susceptibility similar to the thioridazine resistant strains. Since
cardiolipin likely plays a role in resistance towards thioridazine, it might also be important
for the mechanism of action behind the potentiating effect of thioridazine. TDZ is known
to intercalate into the membrane and we show here that TDZ can depolarize the plasma
membrane. However, our results indicate that the membrane potential reducing effect of
TDZ is independent of the resistance mechanism.
Introduction
Methicillin-resistant Staphylococcus aureus (MRSA) is a globally growing health-care problem.
Patients suffering from infections caused by MRSA have a higher mortality [1] and are hospi-
talized longer [2] compared to infections caused by methicillin-susceptible S. aureus (MSSA).
This is partly due to a lack of effective, well-proven antibiotics besides vancomycin. Resistance
PLOS ONE | https://doi.org/10.1371/journal.pone.0201767 August 8, 2018 1 / 17
a1111111111
a1111111111
a1111111111
a1111111111
a1111111111
OPENACCESS
Citation: Wassmann CS, Lund LC, Thorsing M,
Lauritzen SP, Kolmos HJ, Kallipolitis BH, et al.
(2018) Molecular mechanisms of thioridazine
resistance in Staphylococcus aureus. PLoS ONE 13
(8): e0201767. https://doi.org/10.1371/journal.
pone.0201767
Editor: Riccardo Manganelli, University of Padova,
Medical School, ITALY
Received: April 12, 2018
Accepted: July 20, 2018
Published: August 8, 2018
Copyright: © 2018 Wassmann et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which
permits unrestricted use, distribution, and
reproduction in any medium, provided the original
author and source are credited.
Data Availability Statement: All sequencing data
files are available from the NCBI Sequence Read
Archive (SRA)database (accession number
SRP139353).
Funding: The work was supported by the
Lundbeck Foundation (www.lundbeckfonden.com)
for the Pre-Graduate Scholarship (Grant no. 2013-
13618) and Travel Stipend (Grant no. 2014-2664)
to LCL. The work was supported by the Lundbeck
Foundation (www.lundbeckfonden.com) for the
PhD Scholarship (Grant no. R32-A2819) to BHK.
in MRSA constitutes a global health problem, while the discovery and development of novel
antibiotics is stagnating.
In recent years, treatment of infections caused by multi-drug resistant bacteria with antibi-
otic/adjuvant combinations has become a possibility [3]. Thioridazine (TDZ) was originally
developed as an anti-psychotic drug and a member of the phenothiazine family, which mostly
features various neuroleptic and anti-histaminergic drugs. It was brought to market as "Mel-
laril" and approved for treatment of schizophrenia and psychosis; however it was globally with-
drawn in 2005 because of its tendency to cause severe side effects when used regularly. TDZ
has been shown to have a synergistic effect with a β-lactam antibiotic at low concentrations in
vitro by restoring susceptibility to β-lactam antibiotics in otherwise resistant organisms [4, 5].
Thorough evidence of the bactericidal activity of TDZ has been collected, both in vitro and
in vivo [4–12], but the mechanism of action (MOA) remains unknown. The question on how
TDZ and the combination of TDZ and a β-lactam antibiotic reduce the survival of bacterial
growth has not been fully answered yet. Studies on synthetic membranes have shown that
TDZ intercalates in the lipid bilayer through interactions with negatively charged phospholip-
ids at the polar/apolar interface of the bilayer, disturbing various membrane associated pro-
cesses [13]. Whether TDZ increases or decreases the fluidity of membranes is not clear since
studies have reported both outcomes [13, 14]. The precise target of TDZ in the membrane,
and how it affects bacteria like S. aureus, still remains unclear.
The synergistic effect of TDZ in combination with antibiotics has been proven to be inde-
pendent of resistance to DCX [5]. The expression of cell wall and stress response related genes
is affected upon TDZ exposure, including vraSR and the genes regulated by this two-compo-
nent system [6]. vraSR is induced through cell wall damage, indicating that TDZ alone affects
the integrity of the cell wall [6]. Global transcriptional analyses have shown that TDZ exposure
induces genes involved in early stage peptidoglycan biosynthesis [7]. In this study, TDZ was
additionally shown to interfere with the formation of the pentaglycine bridge of peptidoglycan
precursors in the cell wall biosynthesis pathway. This indicates that TDZ has pleiotropic effects
on factors associated with the cytoplasmic membrane and/or cell wall—but the target molecule
remains unknown.
An in vivo study showed that the combination treatment can clear the bacterial load from
the intestine of the nematode model organism, Caenorhabditis elegans, compared to mono-
therapy [8]. Furthermore, recent data showed a reduction of an intraperitoneal infection by
intraperitoneal treatment in mice [9], but not in a porcine aorta graft model experiment,
which revealed no statistical differences for bacteriological endpoints between the treatment
groups [12]. However, in the same porcine model, drug-loaded Interpenetrating polymer net-
works (IPNs) catheters were found to significantly decrease the frequency of central venous
catheter-related infections [10].
The aim of the present study was to identify the mechanism of action for thioridazine and
its ability to potentiate the effect of dicloxacillin. We investigated this by genotypic and pheno-
typic analysis of induced TDZ resistance in MRSA USA300 through a serial passage experi-
ment. Our results suggest that TDZ resistance has similarities to daptomycin resistance and
that cardiolipin takes part in the mechanism of TDZ resistance.
Methods and materials
Strains and growth conditions
The bacterial strain used in this study is the parental S. aureus MRSA strain USA300 FPR3757
(ATCC BAA-1556) [15]. Growth media used are Mu¨ller Hinton broth (MH) (Merck) and
Brain Heart Infusion broth (BHI) (Oxoid). All strains were grown at 37˚C as standard. For
Thioridazine resistance in MRSA
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cloning, E. coli strain IM08B was grown in Lysogeny broth (LB) (Sigma Aldrich). Antibiotics
(chloramphenicol (CHL) and anhydrotetracycline (ATc)) were added when required. See S1
Table for an overview of all strains in the present study.
In vitro selection for increased thioridazine tolerance
The MRSA strain USA300 was passed through multiple cultures with progressively higher
concentrations of TDZ. Following overnight growth, the culture grown at the highest concen-
tration of TDZ was diluted 1:1000 in fresh medium containing an equal or higher ( 10 μg/ml
increments) TDZ concentration and the subsequent culture was allowed to incubate at 37 ˚C
with shaking. Starting with 32 μg/ml TDZ at day 0, the cycle was repeated every day reaching
90 μg/ml TDZ at day 38.
Growth assays
Using an oCelloScope (Philips BioCell A/S), the bacterial density was measured over a period
of 24 hours. The background corrected absorption (BCA) was measured, which roughly trans-
lates to conventional measurements of turbidity. A 96-well plate (Nunc Edge) was prepared
with different concentrations of TDZ and DCX in MH media. Diluted overnight cultures
(OD600nm of 0.005) were added to each well. The plate was incubated at 37 ˚C (without shak-
ing) for 24 hours. For comparison, the same concentrations of TDZ and DCX were used for all
strains which were 16 μg/ml for TDZ and 0.125 μg/ml for DCX which as previously published
shows synergy [5]. Experiments were repeated with at least three biological replicates.
Minimum inhibitory concentrations
The MIC was determined using the broth microdilution method [16]. The MIC was inter-
preted as the lowest concentration at which no bacterial growth was observed. Values given
are the consensus MIC derived from at least two independent determinations. Briefly, MIC
measurements were performed using the MH medium using 96-well plates (Nunc A/S). A
total volume of 100 μL with a bacterial inoculum of 5×105 cfu/mL was incubated with two-fold
dilution series of DCX and/or TDZ at 37˚C for 18–20 hours with shaking. Bacterial growth
was determined by turbidity measurements. Experiments were repeated with at least three bio-
logical replicates.
Purification of genomic DNA
Genomic DNA was purified using the GenElute Bacterial Genomic DNA Kit (Sigma-Aldrich)
according to the manufacturer’s recommendations. The enzymatic lysis solution was prepared
with lysozyme and lysostaphin (Sigma-Aldrich) as recommended by the manufacturer.
DNA sequencing and library preparation
DNA sequencing and library preparation were conducted at the National High-throughput
DNA sequencing Centre at the University of Copenhagen. The complete sequencing data set
is available at the NCBI BioProject database under accession number PRJNA449536 and the
NCBI Sequence Read Archive (SRA) database under accession number SRP139353. Library
preparation was done according to the protocol specified by Meyer and Kircher [17] with a
target insert size of 600 nt. Sequencing was carried out on an Illumina MiSeq benchtop
sequencer as paired end sequencing with a read length of 250 base pair (bp).
Thioridazine resistance in MRSA
PLOS ONE | https://doi.org/10.1371/journal.pone.0201767 August 8, 2018 3 / 17
Preprocessing of reads
Reads were obtained in .fastq format. Sequencing adapters were removed and resulting reads
trimmed according to phred score. Reads below 36 bp in length were discarded.
Identification of variants
Single-nucleotide polymorphisms (SNPs) were identified using three different workflows, two
based on reference sequence alignment and one based on de novo assembly. For sequence
alignment, reads were aligned against the reference genome of S. aureus USA300 FPR3757.
For genome alignment both “Stampy”[18] and “Breseq” [19] were used. For Stampy align-
ments, optical duplicates were removed using “Picard Tools” (http://broadinstitute.github.io/
picard). The “GATK” was used to improve alignment around indels. Variants were called
using GATKs UnifiedGenotyper (UG). For breseq variants, only variants classified as “strong
evidence” were considered. De novo assembly and variant calling based hereupon were con-
ducted using “cortex_var”[20], using the “independent” workflow. Variants identified by
UG and cortex were filtered according to quality scores. All variants were annotated using
“SnpEff”[21] and the impact on protein level estimated using the “Project HOPE”[22] webser-
ver. Variants present in the wild type strain or in only a single mutant strain were discarded.
Phylogenetic analysis
“Wombac” (http://www.vicbioinformatics.com/software.wombac.shtml), using default param-
eters, was used to generate a phylogenetic tree of all sequenced strains.
Creation of deletion mutants
Plasmids for in-frame deletions of relevant genes (rpoC, SAUSA300_0649, SAUSA300_0703,
SAUSA300_0911, pyc, SAUSA300_1119, SAUSA300_1720, SAUSA300_1797, and cls) were con-
structed through splicing by overlap extension (SOE) PCR [23] into the pIMAY plasmid [24].
The specific primers used for creation of deletion mutants can be found in S2 Table. Briefly,
the plasmids containing a sequence up- and downstream of the gene of interest were trans-
formed into Escherichia coli IM08B, purified, and transformed into electrocompetent S. aureus
(USA300). Positive colonies grown on BHI plates containing 20 μg/ml CHL were identified by
colony PCR using primers IM151 and IM152 [24]. Genomic integration was performed in
BHI broth with 20 μg/ml CHL at 28 ˚C overnight (ON). Colony PCR, using the primer pairs
outF & D and A and outR, was conducted to determine, if the knockout construct was inserted
up- or downstream of the gene of interest. Excision of pIMAY plasmid was performed by
repeated overnight culture dilutions in BHI at 28 ˚C for a minimum of 7 days. The culture was
plated on BHI agar plates with and without 1 μg/ml anhydrotetracycline and incubated at
28 ˚C for 2 days. Colonies were subsequent spotted on BHI plates with and without 20 μg/ml
CHL. Verification of plasmid excision was performed by colony PCR with outF and outR
primers. The deletion of the gene was verified by sequencing by Eurofins Genomics for the
genes SAUSA300_0649, SAUSA300_0911, pyc, SAUSA300_1797, and cls. The remaining dele-
tion mutants were unsuccessful for different technical reasons.
Assessment of membrane potential using flow cytometry
Measurement of the membrane potential was conducted using the BacLight Bacterial Membrane
Potential Kit (Invitrogen) in three biological replicates. An overnight culture was diluted to an
OD600nm of 0.02 in BHI and incubated at 37 ˚C until early exponential phase (OD600nm of 0.3).
The culture was then diluted 1:100 in sterile phosphate-buffered saline. Four dilutions were
Thioridazine resistance in MRSA
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made per sample. One sample was treated with 5 μM of CCCP (carbonyl cyanide 3-chlorophe-
nylhydrazone) to depolarize the cells, thereby acting as a depolarized control and another sample
was treated with 16 μg/ml of TDZ and left at room temperature for 5 minutes. The depolarized
control, the TDZ treated sample, and one untreated sample were stained for 15–30 minutes with
30 μM of DiOC2 dye and the last sample was left as an unstained control. After staining, the sam-
ples were analyzed in a BD FACS Aria II flow cytometer (Becton, Dickinson and Company). 104
events were analyzed, while exciting the particles with a laser emitting 488 nm and collecting the
green and red fluorescence. As a measure of the membrane potential, the ratio of the mean red
fluorescence intensity compared to the mean green fluorescence intensity was calculated. Cells
with unaffected membranes will have an accumulation of the dye which causes a red fluores-
cence emission and thus a high red/green ratio whereas cells with affected membranes will have
low dye content causing green fluorescence emission and thus a low red/green ratio.
Results
Generation and sensitivity of the TDZ resistant strains
A serial passage with increasing concentrations of TDZ was conducted to evaluate the poten-
tial of MRSA to acquire resistance towards TDZ (see S1 Fig). The experiment resulted in adap-
tation to TDZ with a two-fold increase in MIC over a period of 39 days.
Growth assays on TDZ resistant strains isolated were conducted at different time points
during the serial passage. The growth of the strains was monitored during exposure to the
combined treatment of TDZ and DCX and compared to the growth when exposed to the indi-
vidual compounds. Fig 1 shows that the synergistic effect between TDZ and DCX disappears
as the bacteria acquire resistance towards TDZ. Wild type, strain 32–3, and strain 40–13
remain susceptible to the combination of TDZ and DCX. There is a significant inhibition of
bacterial growth for these strains, when comparing the combined treatment with monotherapy
(Fig 1a–1c). Strains 50–19, 60–26, 70–31, 80–37, and 90–38 exhibit no difference in inhibition
of growth when comparing combined treatment and monotherapy (Fig 1d–1h). From this, it
can be concluded that synergy is lost at the TDZ concentration which previously gave synergy
in combination with the β-lactam antibiotic DCX. The emergence of resistance in strain 50–19
and later strains indicates key mutational events having taken place in the serial passage after
the culture was exposed to 50 μg/ml of TDZ. On the basis of this finding, strain 50–19 and
later strains were chosen for whole-genome sequencing.
Whole-genome sequencing of TDZ resistant strains
For detection of genotypic changes, whole-genome sequencing was conducted on five TDZ
resistant strains and the wild type, S. aureus USA300 FPR3757. Sequence data were analyzed
in regards to SNPs, insertions, and deletions. Variants were called with three different work-
flows. Comparison of the whole-genome sequences of our isolate of USA300 FPR3757 to
the online genomic sequence revealed SNPs, which were excluded before further analyses of
genomic variations to the TDZ resistant strains. Overall 10 different SNPs and one 13 bp
insertion were detected. Nine of the SNPs were detected through the Stampy, Breseq and
cortex var variant calling. A tenth SNP was only detected through the Stampy and Breseq
workflow. The 13 bp insertion was detected through cortex var and Breseq variant calling,
while the combination of Stampy and UnifiedGenotyper did not detect the mutation. Three
variants were not included for further analysis, since only one workflow identified these (1
Stampy, 2 cortex var). Of the 10 final SNPs, one introduced a premature stop codon, whilst
the others were missense mutations. Details about filtering of the mutations can be seen in
supplementary S2 and S3 Figs. All mutations were confirmed through Sanger sequencing.
Thioridazine resistance in MRSA
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Fig 1. Growth assays. Effect of TDZ (16 μg/ml) and DCX (0.125 μg/ml) on growth and growth inhibition of USA300
wild type and derivative strains 32–3, 40–13, 50–19, 60–26, 70–31, 80–37, and 90–38 obtained from serial passage
experiment with TDZ.
https://doi.org/10.1371/journal.pone.0201767.g001
Thioridazine resistance in MRSA
PLOS ONE | https://doi.org/10.1371/journal.pone.0201767 August 8, 2018 6 / 17
Table 1 show the mutations identified through whole-genome sequencing with indications
of the affected genes, their functions, as well as the probable mutational consequences as
identified by the Project HOPE web server. Biologically, the affected genes can be categorized
into three groups: Cell wall related (SAUSA300_0703, SAUSA300_1720, and cls), cytoplasmic
membrane related (SAUSA300_0649, SAUSA300_0911, and SAUSA300_1720), and others
(rpoC, pyc, SAUSA300_1119, and SAUSA300_1797).
The five TDZ resistant strains were additionally inspected for large insertions and deletions.
No areas with zero coverage longer than 500 bp were detected in the reads of all strains. There-
fore, it is safe to assume that no major deletions occurred in the mutants’ genome under the
serial passage experiment. De novo assembly of unmapped reads resulted in 9 to 14 contigs,
depending on the sample, greater than 1000 bp in length per strain. All contigs mapped to S.
aureus USA300 FPR3757’s plasmid sequences pUSA01, pUSA02 and pUSA03, except one
5386 bp contig, representing a bacteriophage added during sample preparation, PhiX 174 [25].
Therefore, no large insertions were found in the analysis.
Phylogenetic analysis of the TDZ mutants
From the sequencing data, a phylogenetic tree was made (Fig 2). The tree shows two lineages
of bacteria which evolved separately under the serial passage. This coincides with the two dis-
tinct groups of mutations listed in Table 1. Strains 50–19 and 60–26 share mutations in the
Table 1. Mutations identified through whole-genome sequencing of TDZ resistant mutants.
Affected gene Gene function Position Strains Codon
change
AA
change
Effect Domain Probable mutational consequences
rpoC RNA polymerase 590016 50–19
60–26
Cgt = >
Tgt
R = > C Missense N-terminal Lost/affected nucleic acid binding
SAUSA300_0649 Phosphate
transporta
724529 50–19
60–26
70–31
80–37
90–38
aTg = >
aAg
M = > K Missense Putative phosphate transport
regulator
Lost/affected multimeric interactions
SAUSA300_0703 Lipoteichoic acid
synthetasea
778099 70–31
80–37
90–38
Gcc = >
Ccc
A = > P Missense Sulfatase, Alkaline-phospha-
tase-like, core domain
Disturbance of main activity
SAUSA300_0911 Na+/H+-antiportera 999109 70–31 gCc = >
gAc
A = > D Missense Substrate-specific transporter
activity
Affect hydrophobic interactions within the
protein or with membrane lipids
SAUSA300_0911 Na+/H+-antiportera 999438 50–19
60–26
Cga = >
Tga
Stop gained Truncated protein, loss of function
pyc Pyruvate
carboxylase
1109416 70–31
80–37
90–38
aAa = >
aTa
K = > I Missense ATP-binding domain Structural disturbance of domain and loss
of function
SAUSA300_1119 Dihydroxy-acetone
kinasea
1224681 80–37
90–38
Gga = >
Aga
G = > R Missense DAK2 domain Disturbance of conformation
SAUSA300_1720 Peptido-glycan
cleavagea
1903228 70–31
80–37
90–38
Cat = >
Tat
H = > Y Missense Amidase domain, hydrolase
activity
Disturbance of folding, loss of function
SAUSA300_1797 Transcrip-tional
regulatora
1980241 50–19
60–26
Gaa = >
Caa
E = > Q Missense Disturbance of function
cls PG to CL
conversion
2208587 50–16
60–26
13BP
insertion
Frame shift. Loss of function
cls PG to CL
conversion
2209475 70–31
80–37
90–38
gCt = >
gAt
A = > D Missense Cardiolipin synthase,
Phospho-lipase D-like domain
Disturbance of function
a hypothetical protein, function inferred from homologous proteins.
https://doi.org/10.1371/journal.pone.0201767.t001
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genes rpoC, SAUSA300_0911, SAUSA300_1797 and strains 70–31, 80–37 and 90–38 share
mutations in the genes SAUSA300_0649, SAUSA300_0703, pyc, SAUSA300_1119, SAUSA300_
1720, and cls. Strains 70–31, 80–37, and 90–38 are the most resistant strains, therefore muta-
tions in SAUSA300_0649, SAUSA300_0703, pyc, SAUSA300_1119, SAUSA300_1720, and cls
may be of greater interest in regards to TDZ resistance.
Analysis of mutated genes
To clarify the importance of every mutated gene in the TDZ adaptation, single knockout
mutants of the genes with mutations identified through whole-genome sequencing were cre-
ated. We attempted to generate knockout mutants for all 9 genes, but only Δ SAUSA300_0649,
Δ SAUSA300_0911, Δ pyc, Δ SAUSA300_1797, and Δ cls were successfully generated and sub-
jected to further analysis.
For phenotypic analysis of the deletion mutant strains, MICs for TDZ and DCX were
determined. With respect to TDZ, the MIC was unchanged for the deletion mutants of
USA300_0911, pyc, USA300_1797, and USA300_0649 at 64 μg/ml when compared to wild
type. Strain 80–37 and Δ cls exhibited two-fold increased MICs to 128 μg/ml compared to wild
type (Table 2). This indicates that a single mutation in the cls gene may be sufficient to create
Fig 2. Phylogenetic analysis. Comparative phylogenetic tree analysis shows USA300 wild type and TDZ resistant strains based on genome analysis together with
the genomic reference sequence for S. aureus USA300_FPR3757 (NC_007793).
https://doi.org/10.1371/journal.pone.0201767.g002
Table 2. Minimal inhibitory concentrations (MICs) for thioridazine and dicloxacillin. Data given are the mean of at least three replicates ± standard error of the mean
(SEM).
Thioridazine ± SEM (μg/ml) Dicloxacillin ± SEM (μg/ml)
WT 64 ± 16 0.25 ± 0.06
80–37 128 ± 0 0.25 ± 0
Δcls 128 ± 0 0.25 ± 0
ΔSAUSA300_0911 64 ± 30 0.125 ± 0
Δpyc 64 ± 0 0.125 ± 0.03
ΔSAUSA300_1797 64 ± 0 0.5 ± 0.11
ΔSAUSA300_0649 64 ± 0 0.125 ± 0
https://doi.org/10.1371/journal.pone.0201767.t002
Thioridazine resistance in MRSA
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resistance towards TDZ. With respect to DCX, the MICs did not differ considerably from wild
type in any strain.
To further analyze the phenotypes of the deletion mutants, growth assays were conducted
in biological triplicates. The concentration of TDZ was increased in consequence to the TDZ
resistance in the strains. Strains USA300 and 80–37 were used as a negative and positive con-
trol, respectively in regards to TDZ resistance and the efficacy of the combination of TDZ and
DCX. The deletion mutants ΔSAUSA300_0649, Δ SAUSA300_0911, Δ SAUSA300_1797, and Δ
pyc exhibited approximately the same phenotype as the wild type, both when treated with TDZ
alone and the combined treatment, indicating that these genes do not contribute to the TDZ
adaptation (Fig 3). In regards to DCX, the strain Δ SAUSA300_1797 shows an increased resis-
tance, which may imply a role of the gene in DCX resistance. The deletion mutant Δ cls fol-
lowed the growth curve of 80–37, when exposed to 32 μg/ml of TDZ. When exposed to both
TDZ and DCX, the strain exhibits a similar phenotype as the wild type and very different to
80–37. This means that loss of the cls gene in S. aureus leads to a reduced susceptibility towards
TDZ, but not the combination of TDZ and DCX. This suggests that cardiolipin affects the bac-
tericidal effect of TDZ and that it is different from the potentiating effect of TDZ. Further-
more, the comparison between Δ cls and 80–37 when exposed to TDZ and DCX indicates that
other genes than cls are responsible for the reduced susceptibility towards the combined treat-
ment as the synergistic effect is present in Δ cls and not in 80–37. It is therefore likely that TDZ
affects several cellular processes.
Depolarization of cytoplasmic membrane
We evaluated TDZ effects on cell membrane depolarization and potential loss in wild type,
80–37, and Δ SAUSA300_cls strains under sub-inhibitory concentration of TDZ. The red/
green fluorescence ratio for the wild type, 80–37 and Δ SAUSA300_cls is shown in Fig 4. CCCP
was used as positive control for depolarization of the membrane. The same depolarizing effect
can be observed when comparing bacteria treated with TDZ to the untreated controls, showing
that TDZ depolarizes the membrane independently of the genetic background of the strains.
Discussion
Clinical consequences of TDZ resistance
MRSA can acquire TDZ resistance. This resistance may be a problem for the future clinical use
of the combination TDZ and DCX, since the growth assays show that TDZ resistance also
leads to a reduced susceptibility towards the combined treatment. Resistance against TDZ
manifested as a two-fold increase in MIC from 64 μg/ml to 128 μg/ml after exposure to
increasing concentrations of TDZ over a period of 39 days, yet it was not possible to force the
bacteria to a higher MIC, as the bacterial growth was inhibited by concentrations above 90 μg/
ml. Since the steady state concentration of TDZ in plasma is about 1 μg/ml [26], manifestation
of resistance in patients treated with the combined treatment of TDZ and DCX seems unlikely
to occur.
The serial passage was conducted in a monoculture in vitro. However, the conditions that
need to be met for evolution of TDZ resistance could be lower in vivo.
Implication of mutations accumulated under adaptive evolution
experiment
All mutations identified through whole-genome sequencing were systematically investigated
through review of the existing literature and relevant databases. No overlap between the genes
Thioridazine resistance in MRSA
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Fig 3. Growth assays. Effects of TDZ (32 μg/ml) and DCX (0.125 μg/ml) on growth and growth inhibition of USA300
wild type, TDZ resistant strain 80–37, Δ SAUSA300_0649,Δ SAUSA300_0911,Δ SAUSA300_1797, and Δ cls.
https://doi.org/10.1371/journal.pone.0201767.g003
Thioridazine resistance in MRSA
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that were mutated through long-time exposure to TDZ and a microarray study of USA300
exposed to TDZ was found [7]. Each identified mutation was therefore evaluated in regards to
how they compare to current knowledge of the biological effects and MOA of TDZ.
rpoC encodes a DNA directed RNA polymerase subunit. Mutations in the rpoC gene have
been associated with antibiotic resistance towards cephalosporin [27], daptomycin (DAP) [28,
29] and vancomycin [30, 31] in other organisms. Mutations in this gene have also been associ-
ated with optimal growth in minimal media [32], including the MH-medium employed in the
adaptive evolution experiment. We did not succeed in producing an rpoC deletion mutant.
Since RpoC is a component of RNA polymerase, it may not be possible to create a full deletion
of the gene. Generation of the missense mutation may be possible to reproduce, even though
single nucleotide mutations in rpoC have been shown to be unstable [31].
The gene SAUSA300_0649 encodes a putative phosphate transport regulator in the cyto-
plasmic membrane. The amino acid sequence of this transporter shows homology to the phoU
phosphate transport regulator and many other postulated prokaryotic phosphate transport
proteins. Very little information is available on this protein. PhoU impacts on widespread pro-
cesses beyond inorganic phosphate (Pi) transport and acts as a persister switch in E. coli multi-
drug tolerance [33]. The mutations were present in all TDZ resistant strains regardless of
lineage. However, TDZ MICs were unaffected by the deletion of the gene.
SAUSA300_0703 or ltaS encodes a glycerol phosphate lipoteichoic acid synthase in S.
aureus. Lipoteichoic acid (LTA) is one of the major components of the staphylococcal cell
envelope and the enzyme responsible for synthesis of LTA is the membrane embedded LtaS.
In Enterococcus faecium, a lipoteichoic acid synthesis inhibitor has a bactericidal effect in com-
bination with DAP suggesting that the LtaS enzyme is a suitable target for the development of
novel antimicrobial treatment [34]. Multiple studies link defects in the LTA synthesis pathway
to hyper-susceptibility towards DAP. DAP interacts with the bacterial cytoplasmic membrane,
like TDZ, and aggregates there, ultimately leading to a rapid depolarization of the membrane
and inhibition of life sustaining processes in the bacterium [35]. LTA and wall teichoic acids
Fig 4. Assessment of membrane potential using flow cytometry. Membrane depolarization assay showing the effect
of 16 μg/ml TDZ on the membrane potential of USA300 wild type, TDZ resistant strain (80–37), and Δ cls. Bar chart
showing red/green mean fluorescence intensity ratio where a high ratio indicates high membrane potential and a low
ratio a depolarized membrane. CCCP (2-[2-(3-Chlorophenyl)hydrazinylyidene]propanedinitrile) is a oxidative
phosphorylation uncoupler used as a positive control for membrane potential depolarization. Data are normalized
against untreated control and show mean values of three biological replicates and standard deviations.
https://doi.org/10.1371/journal.pone.0201767.g004
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(WTA) play a key role in controlling the net charge of the membrane [36]. TDZ interacts with
the negatively charged phospholipids in the cytoplasmic membrane [13]. Such a change in the
overall membrane charge and composition is seen in the depolarization of the cytoplasmic
membrane by TDZ in this study indicating that an impaired LTS synthesis may explain the
phenotypes of the TDZ resistant strain. The predicted effect of the mutation in the ltaS gene is
to destroy the sulfatase domain of LtaS. It is reasonable to assume that this would disrupt the
protein’s function and result in a lower amount of LTA in the cell envelope. LTA is associated
with protection against cell wall stressors (DAP, vancomycin and others) [37], therefore it
seems unclear how a reduced amount of LTA should confer resistance to TDZ. Unfortunately,
we did not succeed in deleting the ltaS gene in USA300 so its role in TDZ resistance remains
to be clarified.
The gene SAUSA300_0911 encodes a hypothetical monovalent cation proton antiporter-2
(CPA2) family protein and is assumed to be a sodium hydrogen antiporter. No studies investi-
gating antibiotic resistance and this family of transporter proteins have been conducted so far,
making it challenging to estimate the biological relevance of this mutation. Two different
mutations were identified through WGS in this gene which was a missense mutation in
strain 70–31 and a nonsense mutation in strains 50–19 and 60–26. This hypothetical Na+/H+
exchanger could be involved in upholding the proton gradient of the cytoplasmic membrane
and thereby the membrane potential. The proximity to TDZ’s proposed site of action and it
being a nonsense mutation could indicate a role of SAUSA300_0911 in TDZ resistance mecha-
nism. However, deletion of the SAUSA300_0911 gene did not restore the sensitivity to TDZ as
seen by MIC analysis and growth assay.
A missense mutation in the pyc gene encoding a pyruvate carboxylase in S. aureus was iden-
tified in three out of five TDZ resistant mutants. Although pyruvate metabolism is a part of
many important processes in the bacterium, no direct interaction with the cytoplasmic mem-
brane, glycine transport or other processes known to be affected by TDZ has been established,
and a strain with the pyc gene deleted did not show the pyruvate carboxylase to be involved in
the TDZ resistance mechanism.
SAUSA300_1119 is a hypothetical protein showing structural similarity to glycerone (dihy-
droxyacetone) kinases and belongs to a protein family of unknown function that contains an
N-terminal DAK2 domain. No knockout mutant was successfully made for this gene and due
to a general lack of literature indicating any relevancy for TDZ’s MOA or mechanism of resis-
tance (MOR), the significance of the gene cannot be evaluated at this point.
It can be inferred from the sequence of SAUSA300_1720, that the encoded protein is a
homolog of an autolysin in S. aureus subsp. aureus MRSA252. atl is the major autolysin gene in
S. aureus and has been found to have lowered expression levels in vancomycin-intermediate
Staphylococcus aureus (VISA) compared to their vancomycin-sensitive Staphylococcus aureus
(VSSA) parent strains. The reduced atl expression levels result in a thickened cell wall [38, 39].
The mutation in SAUSA300_1720 is predicted to be damaging to the protein. This should have
a similar effect to a reduced expression of the gene, causing a thickened cell wall. Though
promising, we were not able to create a deletion mutation of this gene.
The gene SAUSA300_1797 is inferred to be a transcriptional regulator and is highly con-
served amongst subspecies of S. aureus. This protein is also referred to as SA1665 I S. aureus
N315 or XdrA which has been shown to bind to the mecA promoter in MRSA CHE482. A
deletion of the encoding gene has been shown to increase oxacillin resistance in multiple
MRSA strains. Although SA1665 has been shown to modulate resistance to β-lactams, an effect
on the transcription of mecA could not be proven [40]. We have previously shown that expo-
sure of S. aureus to TDZ reduces the expression of mecA significantly after exposure to DCX
[4]. This effect could be explained by SA1665 being an inhibitor of mecA expression that is
Thioridazine resistance in MRSA
PLOS ONE | https://doi.org/10.1371/journal.pone.0201767 August 8, 2018 12 / 17
activated, when the bacterium is exposed to TDZ. Nevertheless, a deletion mutant of
SAUSA300_1797 did not confirm the gene to be involved in the TDZ resistance mechanism.
The cls gene is the second gene that carries a mutation in all TDZ resistant strains. A 13 bp
insertion in 50–19 and 60–26 induces a shift in reading frame and thereby a nonfunctional
protein. The remaining strains carry a missense mutation, which has been predicted to be
damaging to the protein as the residue is a part of a domain with transferase activity. The cls
gene in S. aureus USA300 is identical to the cls2 gene in other, well-studied isolates of S. aureus.
Peleg et al. [41] sequenced 21 clinical and 12 laboratory-derived DAP resistant strains and
mutations in cls2 were identified in five of the strains. In two of these strains, cls2 was the only
gene carrying a mutant allele, which resulted in a four-fold increase in the MIC. Another study
investigated the transcriptomic effects of DAP resistance in S. aureus and found that the cls
gene was significantly downregulated in the laboratory evolved DAP resistant strains [42]. cls
mutations were also found in DAP resistant Enterococcus faecium strains [43], though when
the mutated allele was transferred to a DAP-susceptible strain, no change in phenotype was
observed [44]. Most papers [41–43] point towards a nonfunctional cardiolipin synthase lead-
ing to resistance to DAP, while another paper [45] associates higher cardiolipin content in
the cytoplasmic membrane with a reduced susceptibility to DAP. Deletion of the cls gene in
USA300 results in an increase in the MIC for TDZ to a similar level as the TDZ resistant strain
(80–37) indicating a very similar proposed MOA for TDZ and DAP.
TDZ depolarizes the cytoplasmic membrane
TDZ intercalates in the bacterial membrane through interaction with negatively charged phos-
pholipids, which is quite similar to DAP’s proposed MOA. Therefore, an interesting question
to answer was whether TDZ also depolarizes the membrane like DAP [46]. As shown, TDZ
lowers the membrane potential drastically, indicating a somewhat similar MOA to DAP.
Strains with a TDZ resistant phenotype (80–37 and Δ cls) exhibit a similar membrane potential
compared to the wild type following TDZ treatment indicating that the membrane potential
reducing effect of TDZ is independent of the resistance mechanism.
Proposed MOA of TDZ
In the search for finding genes directly involved in the TDZ resistance phenotype, generation
of individual deletion mutants revealed no genes solely contributing to the phenotype. Only cls
contributed partly to the phenotype. Hence, several mutations are necessary for the full TDZ
resistance phenotype.
TDZ has an effect on the membrane potential, a similar resistance genotype as DAP and
both compounds exhibit synergy in combination with β-lactam antibiotics, suggesting that the
MOA for these two compounds must be quite similar. To support this, we observed a two-fold
increase in resistance for the TDZ resistant strain 80–37 to DAP compared to wild type (data
not shown).
Cardiolipin plays a key role in the MOR of TDZ and it is therefore very likely to be an
important part of the MOA. TDZ is known to interact with negatively-charged phospholipids,
which could indicate that cardiolipin directly interacts with or binds TDZ. Coupling of these
two hypotheses leads to the following MOA being proposed: When able to pass through the
cell wall, TDZ accumulates in the cytoplasmic membrane through interaction with cardiolipin.
Increasing amounts of TDZ compromise the cytoplasmic membrane, leading to ion leakage
out of the cell, which lowers and disturbs the electrochemical gradient driving membrane
transport of essential molecules. Consequently, this leads to inhibition of life-sustaining pro-
cesses like the cell wall synthesis, which TDZ is known to affect [4, 5].
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Conclusion
In summary, combining drugs to combat antimicrobial resistance has a great potential in the
future but as with all antibiotics, resistance is always an issue. In the present study, we aimed to
reveal the mechanism behind TDZ resistance. We found that S. aureus can become resistant
toward TDZ and that cardiolipin seems to play a role in this mechanism. Furthermore, TDZ
depolarises the cytoplasmic membrane, a mechanism in which cardiolipin does not seem to be
a part of and other genes must be involved.
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